| Authors: |
Weiss SA; Yale University School of Medicine, New Haven, Connecticut., Sznol M; Yale University School of Medicine, New Haven, Connecticut., Shaheen M; University of Arizona Cancer Center, Tucson, Arizona., Berciano-Guerrero MÁ; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain., Couselo EM; Vall d'Hebron University Hospital, Barcelona, Spain., Rodríguez-Abreu D; Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain., Boni V; START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain., Schuchter LM; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Gonzalez-Cao M; Instituto Oncológico, Quirón Dexeus University Hospital, Barcelona, Spain., Arance A; Hospital Clínic Barcelona, Barcelona, Spain., Wei W; Yale University School of Medicine, New Haven, Connecticut., Ganti AK; VA Nebraska Western Iowa Healthcare System and University of Nebraska Medical Center, Omaha, Nebraska., Hauke RJ; Nebraska Cancer Specialists, Omaha, Nebraska., Berrocal A; University General Hospital of Valencia, Valencia, Spain., Iannotti NO; Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida., Hsu FJ; Apexigen America, Inc., San Carlos, California., Kluger HM; Yale University School of Medicine, New Haven, Connecticut. |
